<DOC>
	<DOCNO>NCT00239044</DOCNO>
	<brief_summary>To evaluate whether maintenance renal transplant patient micophenolate mofetil ( MMF ) safely convert EC-MPS , base adverse event acute rejection within 6 month switch MMF EC-MPS regimen .</brief_summary>
	<brief_title>An Open Label Study Evaluate Tolerability Safety Enteric-coated Mycophenolate Sodium ( EC-MPS ) Combination With Cyclosporine Microemulsion ( CsA-ME ) Maintenance Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion criterion 1 . Males female age 18 80 year . 2 . Recipients first secondary cadaveric , live relate unrelated donor kidney transplant least 6 month transplantation . 3 . Patients currently receive CsAME MMF , without corticosteroid part immunosuppressive regimen least 3 month prior Screening . 4 . Patients receive MMF reduce dose prior study entry 5 . Patients stable condition term graft function ( serum creatinine 2.3 mg/dL ( =204 Âµmol/L ) screen baseline , increase 20 % baseline compare value obtain screen ) , change immunosuppressive regimen due graft malfunction , know clinically significant physical and/or laboratory change least 2 month prior enrollment . 6 . Females childbearing potential must negative serum pregnancy test within 7 day prior screen . Effective contraception must use trial , 6 week follow discontinuation study medication , even history infertility . 7 . Patients willing able participate full course study write informed consent obtain . Exclusion Criteria 1 . Multiorgan patient ( e.g. , kidney pancreas ) previous transplant organ different kidney ( secondary kidney transplant allow ) 2 . Evidence graft rejection treatment acute rejection within two month prior Screening . 3 . Patients know hypersensitivity ECMPS component formulation ( e.g. , lactose ) 4 . Patients thrombocytopenia ( &lt; 75,000/mm3 ) , absolute neutrophil count &lt; 1,500/mm3 and/or leukocytopenia ( &lt; 2,500/mm3 ) , and/or hemoglobin &lt; 6.0 g/dL prior enrollment . 5 . Patients receive investigational drug within two week prior Screening ( i.e. , Day 14 runin period ) . 6 . Patients history malignancy within last five year , except excise squamous basal cell carcinoma skin . 7 . Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception 8 . Presence clinically significant infection require continued therapy , severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus would interfere appropriate conduct study . 9 . Known positive HIV and/or Hepatitis B surface antigen positive . 10 . Evidence drug and/or alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Kidney transplant recipient ; Enteric-coated Mycophenolate sodium ( EC-MPS )</keyword>
</DOC>